Macquarie Group
ZNTL icon

Macquarie Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Macquarie Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-272
Closed -$7.44K – 2437
2022
Q2 		$8K Hold
272
– – ﹤0.01% 2480
2022
Q1 		$13 Hold
272
– – ﹤0.01% 2483
2021
Q4 		$23K Sell
272
-261
-49% -$20.2K ﹤0.01% 2365
2021
Q3 		$36K Hold
533
– – ﹤0.01% 2325
2021
Q2 		$28K Buy
+533
New +$28.5K ﹤0.01% 2293

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Macquarie Group's ZNTL Position: Q3 2022 in Review

Macquarie Group sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2022, closing a stake of 272 shares — an estimated $7.44K sold.

Macquarie Group first reported a position in ZNTL in Q2 2021 and held it in 5 quarters. The position peaked at $36K in Q3 2021. 120 funds tracked by Wall St. Rank hold ZNTL as of Q3 2022.

  • Macquarie Group reported no remaining Zentalis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Macquarie Group sold 272 Zentalis Pharmaceuticals shares in Q3 2022, an estimated $7.44K.
  • Macquarie Group first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Macquarie Group's Zentalis Pharmaceuticals position peaked at $36K in Q3 2021.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.